Name (Synonyms) | Correlation | |
---|---|---|
drug3129 | Woebot Substance Use Disorder Wiki | 0.58 |
drug3158 | Zonisamide Wiki | 0.58 |
drug354 | BMS-986256 Wiki | 0.58 |
drug2127 | Placebo (for Zonisamide) Wiki | 0.58 |
drug3268 | famotidine Wiki | 0.58 |
drug357 | BMS-986322 Placebo Wiki | 0.58 |
drug1752 | Milk of magnesia Wiki | 0.58 |
drug356 | BMS-986322 Wiki | 0.58 |
drug2826 | Take Control Wiki | 0.58 |
drug359 | BNT162b1 Wiki | 0.41 |
drug360 | BNT162b2 Wiki | 0.41 |
drug2122 | Placebo Wiki | 0.03 |
Name (Synonyms) | Correlation | |
---|---|---|
D019966 | Substance-Related Disorders NIH | 0.38 |
D004194 | Disease NIH | 0.10 |
Name (Synonyms) | Correlation |
---|
There are 3 clinical trials
Alcoholism is the third leading cause of preventable death in the US, accounting for 80,000 deaths annually. Almost 18 million US adults have alcohol use disorder (AUD); however, approved medications for the treatment of AUD has shown limited effectiveness. Zonisamide (ZON), a broad spectrum anticonvulsant, has proven to be more effective than a placebo in reducing alcohol intake in individuals with alcohol dependence. ZON's mechanism of action seems to be quite distinct from currently approved anti-alcoholism medications, which holds promise for treatment of individuals who are not responsive to conventional medications. However, much remains unknown about ZON's therapeutic mechanisms and ZON's efficacy in treating patients with a diagnosis of AUD. To fill in these gaps, the investigators will conduct a double-blind randomized controlled study that assesses ZON's treatment mechanisms and effectiveness in reducing alcohol consumption in patients with AUD. Participants will be randomized to one of two conditions: 1) treatment with ZON and a computerized psychotherapy platform called Take Control (TC); 2) treatment with a placebo (PLC) and TC. To understand the neurobiology behind ZON's potential therapeutic effects on AUD, fMRI will be used to compare the brain activity of the ZON+TC versus PLC+TC group while participants perform an alcohol and emotional-word Stroop task, as well as an alcohol related cues task.
Description: Drinking measures derived from Time Line Follow Back data will include the percent days drinking, the number of drinks consumed per day, and the percent days heavy drinking. Heavy drinking will be defined as 4 or more drinks per day for women and 5 or more drinks per day for men.
Measure: Alcohol Consumption Time: Change from baseline following 12-week treatmentDescription: The Risk Task (Rogers et al., 1999) measures decision-making under risk.
Measure: Risk Task - Risk Taking Behavior Time: Change from baseline at conclusion of 12-week treatmentDescription: The cued go no-go task (Fillmore, 2003) measures impulse control by the ability to inhibit instigated, "prepotent" responses.
Measure: Cued Go/No-go Task - Impulsivity Time: Change from baseline at conclusion of 12-week treatmentDescription: The Balloon Analogue Risk Task (BART) is a computerized measure of risk taking behavior. The BART models real-world risk behavior through the conceptual frame of balancing the potential for reward versus loss.
Measure: Balloon Analogue Risk Task - Risk Taking Behavior Time: Change from baseline at conclusion of 12-week treatmentDescription: The Continuous Performance Task (CPT) measures brain damage
Measure: Connors Continuous Performance Task - Impulsivity Time: Change from baseline at conclusion of 12-week treatmentThis study seeks to gather data and insight on epidemiologic trends of loneliness and other behaviors in the wake of the CDC recommended "social distancing" during the COVID-19 pandemic. The objective of this study is to use a cross-sectional survey to assess the impact of COVID-19's associated recommendations (social distancing, self-isolation, and self-quarantine) on loneliness and psychosocial symptomatology (depression, anxiety, substance abuse) on young adults (18-35 years old).
Description: University of California Los Angeles ( UCLA) Loneliness Scale is a 20-item self-report questionnaire that evaluates subjective feelings of loneliness and social isolation. Participants rate items on a 4-point Likert scale ranging from 1 (never) to 4 (often).Items are summed to create a score that can range from 20-80, higher scores being indicative of greater loneliness.
Measure: Loneliness as evaluated by the UCLA loneliness scale Time: Day 1Description: Alcohol Use Disorder Identification Test (AUDIT) is a 10-item self-reported questionnaire used to identify individuals whose alcohol consumption could be hazardous for their health. Participants rate items in a 5-point Likert scale, indicating amount (0 to 10 drinks or more), frequency (never to daily or almost daily), and indication of problems caused by alcohol (yes or no). Items were summed up to create a score that can range from 0 to 50. A score of 1 to 7 indicates low risk consumption, whereas a score of 8-15 suggests risky or hazardous drinking, a score of more than 15 is likely to indicate high-risk drinking and alcohol dependence.
Measure: Alcohol Use as evaluated by the AUDIT Time: Day 1Description: The Drug Abuse Screening Test (DAST-10) is a 10-item self-reported screening test that provides a quantitative index of the degree of consequences related to drug abuse. Participants rate items yes or no, positive responses corresponding to 1 point. Items are summed up to create a score that can range from 0-10. A score of 1-2 represents risky behaviors related to drugs, 3-5 represents moderate problems, 6-8 represents substantial problems, and 9-10 represents severe problems.
Measure: Drug Use as evaluated by the DAST-10 Time: Day 1Description: The General Anxiety Disorder Scale (GAD- 7) is a 7- item self-reported screening tool that assess presence and severity of Generalized Anxiety Disorder. Participants rated frequency of problems in a 4-point Likert scale ranging from 0 (not at all) to 3 (nearly every day). Items are summed up to create a score with scores of 5, 10, and 15 being the cut-off points for mild, moderate and severe anxiety, respectively.
Measure: Anxiety as evaluated by GAD-7 Time: Day 1Description: The Center for Epidemiologic Studies Depression scale (CES-D-10) is a 10-item self-reported measure that assesses the frequency of symptoms of depression. Participants rate frequency of symptoms in a 4-point Likert scale from 0 (rare or none of the time) to 3 (most or almost all the time). Items are summed up to create a score that ranges from 0 to 30, with higher scores representing greater depressive symptoms. A score of 16 or more represents clinical depression.
Measure: Depression as assessed by CES-D-10 Time: Day 1The purpose of this study is to test the efficacy of a substance use disorder intervention delivered via a mobile application in an adult population during the COVID-19 pandemic. This study that will test the comparative efficacy of the mobile-app based substance use disorder program to reduce substance use relative to a wait list control condition, and explore between group differences on quality of life indices as well as retention and engagement during COVID-19.
Description: Range from 0-100 (no pain to worst pain imaginable)
Measure: Pain rating Time: Difference between baseline and post-treatment (8 weeks from baseline)Description: Total score between 0-27, higher scores indicate greater levels of depression
Measure: Patient Health Questionnaire-9 (PHQ-9) Time: Difference between baseline and post-treatment (8 weeks from baseline)Description: Total score between 0-21, higher scores indicate greater levels of anxiety
Measure: General Anxiety Disorder-7 (GAD-7) Time: Difference between baseline and post-treatment (8 weeks from baseline)Description: Range from 8 to 32, with higher values indicating higher satisfaction
Measure: Client Satisfaction Questionnaire (CSQ) Time: Post-treatment (8 weeks from baseline)